Please assess the completion status of the following clinical trial:

Trial Title: A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female from 16 to 65 years~* Well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification~* History of partial onset seizures~* Subjects having at least 4 partial onset seizures during the 4-week Baseline Period and at least 2 partial onset seizures during the 3 months prior to Visit 1~* Subjects taking 1 or 2 concomitant Antiepileptic drugs (AED(s)) that have been at a stable dose.~Exclusion Criteria:~* Seizure type IA non-motor as only seizure type~* Seizures occurring only in clusters~* Status epilepticus during the last 2 years before Visit 1~* History of cerebrovascular accident (CVA)~* Presence of any sign suggesting rapidly progressing brain disorder or brain tumor

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo tablets administered twice a day
- Brivaracetam 5 mg/day (Type: EXPERIMENTAL): Brivaracetam 5 mg/day, 2.5 mg administered twice a day
- Brivaracetam 20 mg/day (Type: EXPERIMENTAL): Brivaracetam 20 mg/day, 10 mg administered twice a day
- Brivaracetam 50 mg/day (Type: EXPERIMENTAL): Brivaracetam 50 mg/day, 25 mg administered twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).